サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：がんマイクロバイオームシーケンス市場- 世界の産業規模、シェア、動向、機会、予測、2017年～2027年
市場調査レポート
商品コード
1303137

がんマイクロバイオームシーケンス市場- 世界の産業規模、シェア、動向、機会、予測、2017年～2027年

Cancer Microbiome Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Component, By Technology, By Application, By End User, By company and By Region
出版日: | 発行: TechSci Research | ページ情報: 英文 116 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

がんマイクロバイオームシーケンス市場- 世界の産業規模、シェア、動向、機会、予測、2017年～2027年
出版日: 2023年07月01日
発行: TechSci Research
ページ情報: 英文 116 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のがんマイクロバイオームシーケンス市場は、予測期間2023-2027年に目覚ましい成長を遂げると予測されています。

がんの発生件数の増加や、がん分野におけるマイクロバイオームの可能性の重視の高まりなどの主な要因が、市場の成長に拍車をかけています。マイクロバイオームとは、唾液、皮膚層、人体の口腔粘膜、消化管などの環境で増殖または存在する微生物のコミュニティです。マイクロバイオームシークエンシングは、ヒトの微生物をより深く理解するために、ヒトの体内あるいは体外に存在する微生物群を研究・解析するために使用される貴重なツールです。マイクロバイオーム研究の主な目的は、ヒトの健康と病気における微生物の役割と機能を理解することです。市場の成長を支えるその他の要因としては、シーケンシングのコスト低下、研究開発活動の活発化、世界のがん患者数の急激な増加、臨床試験件数の増加、医師をサポートするためのマイクロバイオームに基づく新規診断ツールの開発増加、バイオテクノロジー企業による投資の増加などが挙げられる、疾患の診断と早期発見のためのマイクロバイオームシーケンスサービスに対する需要の増加、世界人口の増加、マイクロバイオームシーケンス技術の使用に対する意識の高まり、ヘルスケア支出の増加、ヒトの健康と疾患におけるマイクロバイオームの役割の理解に対する研究者の関心の高まり、新興サブマーケットに対する計り知れない可能性。

がん罹患率の上昇が市場成長を支えます。

肺がん、子宮頸がん、乳がん、皮膚がん、咽頭がんなど、がんの罹患率の増加が市場の成長を後押ししています。WHOによると、2020年には、がんは世界中で主要な死因となっており、死亡者数は約1,000万人、死亡者数の約6人に1人と報告されています。最も多いがんは、肺がん、結腸・直腸がん、前立腺がん、乳がんです。アルコールの摂取、タバコの使用、不健康な食事の選択、座りっぱなしのライフスタイルなどが原因でがんに罹患する症例が急増しています。そのため、ががんマイクロバイオームシーケンスのニーズが高まっており、市場の成長を後押ししています。WHOによると、多くのがんは早期に発見されれば効果的な治療が可能です。

マイクロバイオームの可能性に対する研究者の注目の高まりとバイオテクノロジー企業からの支援の高まり。

様々ながんの診断と予防に対するマイクロバイオームの可能性への注目の高まりが、市場の成長を後押ししています。さまざまな研究者が、がん分野におけるマイクロバイオームの可能性を調査・研究しています。研究者たちは、がんの進行や発現に対するマイクロバイオームの影響に関する洞察を解明するために、バイオテクノロジー企業の支援を受けています。さらに、がんマイクロバイオームシーケンスサービスおよび製品の開発は、研究コミュニティがマイクロバイオームと関連する新規がんバイオマーカーを発見するための効果的な戦略を構築するのに役立っています。

利用可能なカスタマイズ

TechSci Researchは、所定の市場データを用いて、企業の特定のニーズに応じてカスタマイズを提供します。レポートでは以下のカスタマイズが可能です：

企業情報

  • 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のがんマイクロバイオームシーケンス市場に与える影響

第5章 顧客の声

第6章 がんマイクロバイオームシーケンスの世界市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • コンポーネント別
    • 技術別
    • アプリケーション別
    • エンドユーザー別
    • 企業別
    • 地域別
  • 市場マップ

第7章 北米のがんマイクロバイオームシーケンス市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • コンポーネント別
    • 技術別
    • アプリケーション別
    • エンドユーザー別
    • 国別
  • 北米国別分析
    • 米国
    • カナダ
    • メキシコ

第8章 欧州のがんマイクロバイオームシーケンス市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • コンポーネント別
    • 技術別
    • アプリケーション別
    • エンドユーザー別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第9章 アジア太平洋地域のがんマイクロバイオームシーケンス市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • コンポーネント別
    • 技術別
    • アプリケーション別
    • エンドユーザー別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第10章 南米のがんマイクロバイオームシーケンス市場展望

  • 市場規模および予測
    • 金額ベース
  • 市場シェアと予測
    • コンポーネント別
    • 技術別
    • アプリケーション別
    • エンドユーザー別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカのがんマイクロバイオームシーケンス市場展望

  • 市場規模および予測
    • 金額ベース
  • 市場シェアと予測
    • コンポーネント別
    • 技術別
    • アプリケーション別
    • エンドユーザー別
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • トルコ
    • エジプト

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向と発展

第14章 競合情勢

  • Illumina, Inc.
  • Eurofins Scientific SE
  • QIAGEN NV
  • Thermo Fischer Scientific, Inc.
  • Oxford Nanopore Technologies plc.
  • OraSure Technologies, Inc.
  • Pacific Biosciences of California, Inc.
  • Psomagen, Inc
  • Prescient Medicine Holdings, Inc.
  • Micronoma Inc.

第15章 戦略的提言

目次
Product Code: 14153

The global cancer microbiome sequencing market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors, including growing occurrences of cancer and increasing emphasis on the microbiome's potential in the field of cancer, are fueling the growth of the market. Microbiomes are the community of microorganisms that grow or exist in an environment, such as saliva, skin layers, oral mucosa of the human body, and the gastrointestinal tract. Microbiome sequencing is a valuable tool that is used to study and analyze the microbes groups located in or out of the human body to have a better understanding of human microbes. The main aim of a microbiome research study is to understand the role and function of microbes in human health and disease. The other factors supporting the market's growth are decreasing cost of sequencing, the rise in R&D activities, the exponential rise in the number of cancer cases worldwide, the increasing number of clinical trials, the rise in the development of novel diagnostic tools based on the microbiome for supporting physicians, increasing investments by biotechnology companies, rise in demand for microbiome sequencing services for diagnosis and early detection of the diseases, rise in world population, growing awareness of the use of microbiome sequencing technology, rise in the healthcare expenditure, rising interest of researchers in understanding the role of the microbiome in human health and disease, and immense potential for emerging submarkets.

The rising Prevalence of Cancer supports Market Growth.

Growing incidences of cancer, such as lung, cervical, breast, skin, throat, and others, are augmenting the growth of the market. According to WHO, in 2020, cancer is a major cause of death across the world, reporting approximately 10 million deaths, or about one in six deaths. The most common cancers are lung, colon and rectum, prostate cancers, and breast. There is a surge in the number of cases suffering from cancer caused due to consumption of alcohol, tobacco use, unhealthy eating choices, and sedentary lifestyle. Therefore, the need for cancer microbiome sequencing is rising, which in turn, bolsters the growth of the market. As per WHO, many cancers can be treated effectively if detected in an early stage.

Increasing Emphasis by Researchers on the Microbiome's Potential and Rising Support from Biotechnology Companies.

The rising focus on the microbiome's potential to diagnose and prevent various cancers is fueling the growth of the market. Various researchers are studying and researching the microbiome's potential in the field of cancers. Researchers are being supported by biotech companies to unravel insights pertaining to the microbiome's influence on cancer progression and manifestation. Furthermore, the development of cancer microbiome sequencing services and products has aided the research community in creating effective strategies for discovering novel cancer biomarkers allied with the microbiome, which could be used for the development of cancer microbiome sequencing products for clinical use.

Market Segmentation

The global cancer microbiome sequencing market is segmented into components, technology, application, end-user, and company. Based on components, the market is divided into kits & assays, software, and services. Based on technology, the market is divided into next-generation sequencing and polymerase chain reaction. Based on application, the market is divided into translational research and clinical diagnostics. Based on end-user, the market is divided into biotechnology & pharmaceutical companies, academic & research institutions, hospitals & clinics, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising incidences of cancer and a rise in R&D activities in the country.

Market Players

Illumina, Inc., Eurofins Scientific SE, QIAGEN NV, Thermo Fischer Scientific, Inc., Oxford Nanopore Technologies plc., OraSure Technologies, Inc., Pacific Biosciences of California, Inc., Psomagen, Inc, Prescient Medicine Holdings, Inc., and Micronoma Inc. are some of the leading companies operating in the market.

Report Scope

In this report, global cancer microbiome sequencing market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Cancer Microbiome Sequencing Market, By component:

  • Kits & Assays
  • software
  • Services

Cancer Microbiome Sequencing Market, By technology:

  • Next-Generation Sequencing
  • Polymerase Chain Reaction

Cancer Microbiome Sequencing Market, By application:

  • Translational Research
  • Clinical Diagnostics

Cancer Microbiome Sequencing Market, By End User:

  • Biotechnology & Pharmaceutical Companies,
  • Academic & Research Institutions
  • Hospitals & Clinics
  • Others

Cancer Microbiome Sequencing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Cancer Microbiome Sequencing Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Cancer Microbiome Sequencing Market

5. Voice of Customer

6. Global Cancer Microbiome Sequencing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component (Kits & Assays, Software, Services)
    • 6.2.2. By Technology (Next Generation Sequencing v/s Polymerase Chain Reaction)
    • 6.2.3. By Application (Translational Research v/s Clinical Diagnostics)
    • 6.2.4. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Hospitals & Clinics, Others)
    • 6.2.5. By Company (2021)
    • 6.2.6. By Region
  • 6.3. Market Map

7. North America Cancer Microbiome Sequencing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Cancer Microbiome Sequencing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Component
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. Canada Cancer Microbiome Sequencing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Component
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. Mexico Cancer Microbiome Sequencing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Component
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User

8. Europe Cancer Microbiome Sequencing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Cancer Microbiome Sequencing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. Germany Cancer Microbiome Sequencing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. United Kingdom Cancer Microbiome Sequencing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. Italy Cancer Microbiome Sequencing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Component
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Spain Cancer Microbiome Sequencing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Component
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. Asia-Pacific Cancer Microbiome Sequencing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Cancer Microbiome Sequencing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. India Cancer Microbiome Sequencing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. Japan Cancer Microbiome Sequencing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User
    • 9.3.4. South Korea Cancer Microbiome Sequencing Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Component
        • 9.3.4.2.2. By Technology
        • 9.3.4.2.3. By Application
        • 9.3.4.2.4. By End User
    • 9.3.5. Australia Cancer Microbiome Sequencing Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Component
        • 9.3.5.2.2. By Technology
        • 9.3.5.2.3. By Application
        • 9.3.5.2.4. By End User

10. South America Cancer Microbiome Sequencing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cancer Microbiome Sequencing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Argentina Cancer Microbiome Sequencing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. Colombia Cancer Microbiome Sequencing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Middle East and Africa Cancer Microbiome Sequencing Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Component
    • 11.2.2. By Technology
    • 11.2.3. By Application
    • 11.2.4. By End User
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Cancer Microbiome Sequencing Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Component
        • 11.3.1.2.2. By Technology
        • 11.3.1.2.3. By Application
        • 11.3.1.2.4. By End User
    • 11.3.2. Saudi Arabia Cancer Microbiome Sequencing Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Component
        • 11.3.2.2.2. By Technology
        • 11.3.2.2.3. By Application
        • 11.3.2.2.4. By End User
    • 11.3.3. UAE Cancer Microbiome Sequencing Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Component
        • 11.3.3.2.2. By Technology
        • 11.3.3.2.3. By Application
        • 11.3.3.2.4. By End User
    • 11.3.4. Turkey Cancer Microbiome Sequencing Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Component
        • 11.3.4.2.2. By Technology
        • 11.3.4.2.3. By Application
        • 11.3.4.2.4. By End User
    • 11.3.5. Egypt Cancer Microbiome Sequencing Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Component
        • 11.3.5.2.2. By Technology
        • 11.3.5.2.3. By Application
        • 11.3.5.2.4. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Illumina, Inc.
  • 14.2. Eurofins Scientific SE
  • 14.3. QIAGEN NV
  • 14.4. Thermo Fischer Scientific, Inc.
  • 14.5. Oxford Nanopore Technologies plc.
  • 14.6. OraSure Technologies, Inc.
  • 14.7. Pacific Biosciences of California, Inc.
  • 14.8. Psomagen, Inc
  • 14.9. Prescient Medicine Holdings, Inc.
  • 14.10. Micronoma Inc.

15. Strategic Recommendations